Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AVEO Pharmaceuticals stock | 5.91

Own AVEO Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

AVEO Pharmaceuticals, Inc is a biotechnology business based in the US. AVEO Pharmaceuticals shares (AVEO) are listed on the NASDAQ and all prices are listed in US Dollars. AVEO Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around USD$28 million.

How to buy shares in AVEO Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AVEO Pharmaceuticals. Find the stock by name or ticker symbol: AVEO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AVEO Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.91, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AVEO Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AVEO Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AVEO Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, AVEO Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$5.91, which is 9.98% up on its pre-crash value of USD$5.32 and 1,121.07% up on the lowest point reached during the March crash when the shares fell as low as USD$0.484.

If you had bought USD$1,000 worth of AVEO Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$5,117.20 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$11,543.00.

AVEO Pharmaceuticals share price

Use our graph to track the performance of AVEO stocks over time.

AVEO Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$5.91
52-week range USD$0.4653 - USD$10.32
50-day moving average USD$5.8326
200-day moving average USD$5.6981
Wall St. target price USD$12
PE ratio 84.8
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.028

Buy AVEO Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AVEO Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AVEO Pharmaceuticals price performance over time

Historical closes compared with the close of $5.91 from 2020-11-16

1 week (2020-11-17) -0.34%
1 month (2020-10-27) 4.05%
3 months (2020-08-25) 22.61%
6 months (2020-05-23) N/A
1 year (2019-11-25) 875.09%
2 years (2018-11-23) 169.86%
3 years (2017-11-24) 94.41%
5 years (2015-11-25) 392.50%

Is AVEO Pharmaceuticals under- or over-valued?

Valuing AVEO Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AVEO Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AVEO Pharmaceuticals's P/E ratio

AVEO Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 85x. In other words, AVEO Pharmaceuticals shares trade at around 85x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

AVEO Pharmaceuticals financials

Revenue TTM USD$28 million
Gross profit TTM USD$10.8 million
Return on assets TTM -6.3%
Return on equity TTM -14.97%
Profit margin -13.27%
Book value $1.862
Market capitalisation USD$152 million

TTM: trailing 12 months

Shorting AVEO Pharmaceuticals shares

There are currently 1.1 million AVEO Pharmaceuticals shares held short by investors – that's known as AVEO Pharmaceuticals's "short interest". This figure is 1.4% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting AVEO Pharmaceuticals shares can be evaluated.

AVEO Pharmaceuticals's "short interest ratio" (SIR)

AVEO Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AVEO Pharmaceuticals shares currently shorted divided by the average quantity of AVEO Pharmaceuticals shares traded daily (recently around 648232.55813953). AVEO Pharmaceuticals's SIR currently stands at 1.72. In other words for every 100,000 AVEO Pharmaceuticals shares traded daily on the market, roughly 1720 shares are currently held short.

However AVEO Pharmaceuticals's short interest can also be evaluated against the total number of AVEO Pharmaceuticals shares, or, against the total number of tradable AVEO Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVEO Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AVEO Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0481% of the tradable shares (for every 100,000 tradable AVEO Pharmaceuticals shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AVEO Pharmaceuticals.

Find out more about how you can short AVEO Pharmaceuticals stock.

AVEO Pharmaceuticals share dividends

We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months.

Have AVEO Pharmaceuticals's shares ever split?

AVEO Pharmaceuticals's shares were split on a 1:10 basis on 20 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for AVEO Pharmaceuticals shares which in turn could have impacted AVEO Pharmaceuticals's share price.

AVEO Pharmaceuticals share price volatility

Over the last 12 months, AVEO Pharmaceuticals's shares have ranged in value from as little as $0.4653 up to $10.32. A popular way to gauge a stock's volatility is its "beta".

AVEO.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 1.3988. This would suggest that AVEO Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AVEO Pharmaceuticals overview

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site